Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Pembrolizumab Keytruda ,Matthews Johnson ,Indiana University Iu School Of Medicine ,Garyj Becker Professor Of Radiology Research ,Radiology Research ,Indiana University ,Barcelona Clinic Liver Cancer ,